Navigation Links
US FDA Admits Risks of Mercury Dental Fillings, Settles Lawsuit
Date:6/5/2008

Statement of Michael Bender, Plaintiff

WASHINGTON, June 5 /PRNewswire-USNewswire/ -- "After 32 years of delay, the Food and Drug Administration has finally agreed to comply with the law and set a date to classify mercury amalgam as a substance that poses a health risk to pregnant women and unborn babies, and children. This about-face resulted from settling, earlier this week, our lawsuit, Moms Against Mercury et al. v. Von Eschenbach, Commissioner, et al. The FDA must now finish classification within one year of the close of the public comment period on its amalgam policy, that is, by July 28, 2009. The FDA also agreed to and, with uncharacteristic speed, has already changed its website on mercury amalgam -- dramatically.

Gone are all of FDA's claims that no science exists that amalgam is unsafe, or that other countries have acted for environmental reasons only, or that the 2006 FDA advisory panel affirmed amalgam's safety, all of which are untrue. Instead, the FDA has moved to a more neutral course, while still recognizing the serious health risks posed by amalgam in particular for children and unborn children, for pregnant women, and for those with mercury immuno-sensitivity.

The Updated June 3, 2008 FDA website (see: http://www.fda.gov/cdrh/consumer/amalgams.html) now states, for example:

"Dental amalgams contain mercury, which may have neurotoxic effects on the nervous systems of developing children and fetus."

"Pregnant women and persons who may have a health condition that makes them more sensitive to mercury exposure, including individuals with existing high levels of mercury bioburden, should not avoid seeking dental care, but should discuss options with their health practitioner."

In September 2006, an advisory panel to the FDA reviewed FDA's research and heard presentations from the public about the benefits and risks of mercury and amalgam. The joint committee concluded with personal recommendations by the members. These include that FDA should:

Consider informed consent for patients receiving amalgam

Consider labeling changes restricting its use in pregnant woman and children

Consider the relevancy of the "precautionary principle"

You can read the summary of the FDA advisory panel meeting at: http://www.fda.gov/cdrh/meetings/090606-summary.html

The FDA website now also states that "Some other countries follow a 'precautionary principle' and avoid the use of dental amalgam in pregnant women. The FDA provides links to advice about dental amalgams from regulatory agencies in other countries:

Canada: http://www.hc-sc.gc.ca/ahc-asc/media/nr-cp/1996/1996_63_e.html

France: http://afssaps.sante.fr/ang/pdf/amalgam.pdf

Sweden: http://www.kemi.se/templates/Page.aspx?id=5233 "

The plaintiffs included a team of four nonprofit groups, two public officials, three dental professionals, and two consumer victims: Moms Against Mercury (Amy Carson and Angela Medlin), Connecticut Coalition for Environmental Justice (Dr. Mark Mitchell), Oregonians for Life (Mary Starrett), mercury expert Michael Bender (as a of the Vermont Advisory Committee on Mercury Pollution), Arizona Senator Karen Johnson, Dr. Andy Landerman, Dr. Corrie Crowe, dental assistant Karen Palmer, consumer advocates Linda Brocato and Anita Vazquez Tibau, and Consumers for Dental Choice.

For More Information: http://www.mercurypolicy.org


'/>"/>
SOURCE Mercury Policy Project
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Sutter Admits: Closing St. Lukes Likely to Reduce Charity Care
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Informational handout key to giving parents a better understanding of CT radiation risks
4. Stanford study highlights cost-effective method of lowering heart disease risks
5. Hispanic Teens Take More Skin Cancer Risks
6. Smoking increases risks for head and neck cancers for men and women
7. Case Management Cost-Effective Way to Cut Heart Risks
8. National Council of Negro Women (NCNW) Partners With Sherwin-Williams to Target Lead Risks in Neglected Housing
9. Diabetes Drug Avandia Boosts Heart Risks: Study
10. Federal research plan to determine nanotech risks fails to deliver
11. AHRQ and FDA to Collaborate in Largest Study Ever of Possible Heart Risks with ADHD Medications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... 06, 2016 , ... The Behavioral Health Center of Excellence ... organization as a top behavioral service provider in the country. The award celebrates ... satisfaction and qualifications, and consumer satisfaction. These areas are measured via a wide-ranging ...
(Date:12/6/2016)... ... December 06, 2016 , ... Experimentation involving human stem ... largely due to its potential for revolutionizing human disease treatment. There are multiple ... pluripotent stem cells (hiPSCs). , Both platforms have distinct advantages and disadvantages, ...
(Date:12/6/2016)... ... 06, 2016 , ... METTLER TOLEDO has launched its online ... white papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, brochures, datasheets, user ... documents, webinars and videos available online, visit the METTLER TOLEDO Expertise Library ...
(Date:12/6/2016)... ... ... 'Tis the season for family, festivity, food and fun! Temptation abounds, and ... eating healthy, staying active, and taking medication and doing daily foot health checks (a ... "Shopping trips, parties and family gatherings can take their toll on our feet during ...
(Date:12/6/2016)... B.C., Canada (PRWEB) , ... December 06, 2016 ... ... (STC) announce the availability of the newly updated International Audit Protocol Consortium (IAPC) ... use IAPC EHS audit protocols to understand the scope of their EHS regulatory ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Nov. 29, 2016 Several leading Alzheimer,s ... Accera, Inc. at 11 a.m. EST on ... Conference on Clinical Trials for Alzheimer,s Disease (CTAD). The ... in Alzheimer,s disease and therapeutic targets that address deficient ... "Following the recent failure of another therapy targeting the ...
(Date:12/5/2016)... , Dec 5, 2016 Research ... Market by Product (Instruments, Consumables), Application (Biomedical & Biochemical Research, Disease ... - Global Forecasts to 2021" report to their offering. ... , , ... USD 730.7 Million in 2021 from USD 574.8 Million in 2016, ...
(Date:12/5/2016)... PUNE, India , December 5, 2016 ... Market by Product Type and by Application - Global Opportunity Analysis and Industry ... in 2015, and is expected to reach $5,255 million by 2022, growing at ... market in 2015 with more than four-fifths share. ... ...
Breaking Medicine Technology: